The Impact of Human Immunodeficiency Virus (HIV) Co-Infection on the Economic Burden of Cutaneous Leishmaniasis (CL) in Brazil and Potential Value of New CL Drug Treatments

Kruchten, Stephanie; Bacon, Kristina M.; Lee, Bruce Y.

doi:10.4269/ajtmh.13-0309

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One disease can worsen the symptoms and clinical outcomes of another disease (e.g. HIV infection can lead to greater disfigurement caused by cutaneous leishmaniasis (Kruchten et al, 2014)) and thus alter the resulting epidemiological, clinical and economic impact (Abuhab et al, 2013;Fincham et al, 2003;Spiegel et al, 2003).…”

Section: Health Effectsmentioning

confidence: 99%

Economic and Financial Evaluation of Neglected Tropical Diseases

Lee

Bartsch

Gorham

2015

Advances in Parasitology

Self Cite

View full text Add to dashboard Cite

Section: Health Effectsmentioning

confidence: 99%

Economic and Financial Evaluation of Neglected Tropical Diseases

Lee

Bartsch

Gorham

2015

Advances in Parasitology

Self Cite

View full text Add to dashboard Cite

“…Although there is no human vaccine for leishmaniasis due to resistance, safety and price, there are speci c treatments for each species, and leishmaniasis affects the poorest sections of low-income societies (121)(122)(123). Advances in omics technologies (genomics, transcriptomics, and proteomics) provide essential tools to improve our current understanding of the molecular biology of Leishmania for the development of new alternatives to anti-leishmania therapies (124).…”

Section: Introductionmentioning

confidence: 99%

A perspective on human leishmaniasis and new methods with therapeutic strategies for prevention, diagnosis, and treatment

Abbasi

Saeedi

2022

Preprint

View full text Add to dashboard Cite

Human leishmaniasis is a complex skin infection that imposes a heavy burden on many tropical and subtropical developing countries and is caused by over 20 species of Leishmaniaparasite and they are transmitted by several sandfly species. The disease is mainly associated with disfiguring scars and major social stigma during infection. Disease severity appears to depend on many factors, including parasite species, host, endemic area, socioeconomic status, and access to health facilities. Despite the many studies that have been conducted on current and new treatments, the treatment outcomes of leishmaniasis remain controversial, possibly because of the knowledge gaps that still exist. Varying responses to current leishmania treatments have become a major drawback in disease control. The lack of information on critical analyses of the results of such studies is a barrier to overall understanding. Based on the currently available literature on treatment outcomes, we discuss the most effective doses, drug susceptibilities/resistances, and treatment failures of Leishmania for monotherapy and combination therapy. This review focuses on the available therapies for leishmaniasis caused by different Leishmania species, with insights into their species-specific efficacy, which will inform the selection of drugs for the treatment and control of leishmaniasis. For this aim, the search was conducted in electronic databases of PubMed, Scopus, web of sciences and Google scholar. The specific search medical subject headings (MeSH) terms include “leishmaniasis,” “leishmaniasis Prevention,” “cutaneous leishmaniasis,” “Leishmaniasis Diagnosis”, “Leishmaniasis Treatment”, “Leishmaniasis Drug”, “Leishmaniasis Parasite”, “Leishmaniasis Cutaneous”, “Rural leishmaniasis”, “Urban leishmaniasis”, “Dry leishmaniasis”, “Wet leishmaniasis”, “Human leishmaniasis”, “Leishmania donovani”, “Leishmaniasis trials”, “leishmaniasis vectors”, “leishmaniasis reservoirs” were conducted and articles with English titles and abstracts were screened and selected, and finally related full-text articles were studied and used in writing a review article.

show abstract

Addressing the Molecular Biology of Leishmania for Drug Development

Norris-Mullins¹,

Morales²

2017

Drug Discovery for Leishmaniasis

View full text Add to dashboard Cite

Leishmaniasis is a disease caused by protozoan parasites of the genus Leishmania. More than 20 Leishmania species infect humans and the disease is endemic in several areas of the Old and New World. Existing therapies for leishmaniasis are inadequate due to resistance, safety and cost, underscoring the necessity for safer therapies with alternative modes of action. The entry of molecular biology with its elucidation of the genomics and proteomics of these organisms has provided increasingly sophisticated explanations of their unique mechanisms to adapt to intense environmental pressures. An interesting feature of the Leishmania (and other trypanosomatids) genome is the unusual nature of transcription and RNA processing. Protein-coding genes are organized into long gene clusters, and the resulting polycistronic RNAs are post-transcriptionally processed into mature mRNAs by concomitant trans-splicing and polyadenylation. These and other unique features are not shared with its host, thus offering new and exciting new avenues for therapeutic intervention.

show abstract

The Impact of Human Immunodeficiency Virus (HIV) Co-Infection on the Economic Burden of Cutaneous Leishmaniasis (CL) in Brazil and Potential Value of New CL Drug Treatments

Cited by 4 publications

References 29 publications

Economic and Financial Evaluation of Neglected Tropical Diseases

Economic and Financial Evaluation of Neglected Tropical Diseases

A perspective on human leishmaniasis and new methods with therapeutic strategies for prevention, diagnosis, and treatment

Addressing the Molecular Biology of Leishmania for Drug Development

Contact Info

Product

Resources

About